JPWO2021216729A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021216729A5 JPWO2021216729A5 JP2022563941A JP2022563941A JPWO2021216729A5 JP WO2021216729 A5 JPWO2021216729 A5 JP WO2021216729A5 JP 2022563941 A JP2022563941 A JP 2022563941A JP 2022563941 A JP2022563941 A JP 2022563941A JP WO2021216729 A5 JPWO2021216729 A5 JP WO2021216729A5
- Authority
- JP
- Japan
- Prior art keywords
- genetically engineered
- cell
- engineered human
- gene
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063013387P | 2020-04-21 | 2020-04-21 | |
| US63/013,387 | 2020-04-21 | ||
| US202063056460P | 2020-07-24 | 2020-07-24 | |
| US63/056,460 | 2020-07-24 | ||
| PCT/US2021/028427 WO2021216729A1 (en) | 2020-04-21 | 2021-04-21 | Cellular vaccine platform and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023522715A JP2023522715A (ja) | 2023-05-31 |
| JPWO2021216729A5 true JPWO2021216729A5 (https=) | 2024-05-02 |
| JP2023522715A5 JP2023522715A5 (https=) | 2024-05-02 |
Family
ID=78269922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022563941A Pending JP2023522715A (ja) | 2020-04-21 | 2021-04-21 | 細胞ワクチンプラットフォーム及び使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230293692A1 (https=) |
| EP (1) | EP4138893A4 (https=) |
| JP (1) | JP2023522715A (https=) |
| CN (1) | CN115916252A (https=) |
| AU (1) | AU2021259612A1 (https=) |
| CA (1) | CA3176416A1 (https=) |
| WO (1) | WO2021216729A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3901261A1 (en) | 2020-04-22 | 2021-10-27 | BioNTech RNA Pharmaceuticals GmbH | Coronavirus vaccine |
| EP4149525A4 (en) * | 2020-05-15 | 2024-08-28 | Rxcell Inc. | HYPOIMMUNOGENIC CELLS AND THEIR USES IN IMMUNE RESPONSES |
| CN113861283B (zh) * | 2021-03-24 | 2024-12-06 | 深圳市新靶向生物科技有限公司 | 一种与肺癌驱动基因突变相关的抗原肽及其应用 |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| WO2023129993A2 (en) * | 2021-12-29 | 2023-07-06 | Intima Bioscience, Inc. | Antigen delivery platform and methods of use |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| WO2024107420A1 (en) * | 2022-11-15 | 2024-05-23 | The Board Of Trustees Of The Leland Stanford Junior University | Hypoallogenic-immunogenic pluripotent stem cells as anti-cancer vaccine |
| CN118440905A (zh) * | 2024-03-12 | 2024-08-06 | 福建省农业科学院畜牧兽医研究所 | 一株鸭短喙矮小综合征病毒sbdsv ma株选育方法及其在活疫苗的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7129042B2 (en) * | 2003-11-03 | 2006-10-31 | Diagnostic Hybrids, Inc. | Compositions and methods for detecting severe acute respiratory syndrome coronavirus |
| EP2849779B1 (en) * | 2012-05-16 | 2021-01-06 | Adelaide Research & Innovation Pty Ltd. | Cellular vaccine and method of inducing an immune response in a subject |
| AU2016211671B2 (en) * | 2015-01-26 | 2022-05-26 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| CA3003152A1 (en) * | 2015-11-04 | 2017-05-11 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| WO2018073391A1 (en) * | 2016-10-19 | 2018-04-26 | Cellectis | Targeted gene insertion for improved immune cells therapy |
| CN110177869A (zh) * | 2017-01-13 | 2019-08-27 | 加利福尼亚大学董事会 | 免疫改造的多能细胞 |
| US11505782B2 (en) * | 2018-06-04 | 2022-11-22 | Calidi Biotherapeutics, Inc. | Cell-based vehicles for potentiation of viral therapy |
-
2021
- 2021-04-21 EP EP21793758.0A patent/EP4138893A4/en active Pending
- 2021-04-21 AU AU2021259612A patent/AU2021259612A1/en active Pending
- 2021-04-21 CN CN202180035794.3A patent/CN115916252A/zh active Pending
- 2021-04-21 WO PCT/US2021/028427 patent/WO2021216729A1/en not_active Ceased
- 2021-04-21 JP JP2022563941A patent/JP2023522715A/ja active Pending
- 2021-04-21 CA CA3176416A patent/CA3176416A1/en active Pending
-
2022
- 2022-10-20 US US18/048,230 patent/US20230293692A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bengtsson et al. | Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice | |
| Leitner et al. | DNA and RNA-based vaccines: principles, progress and prospects | |
| Berglund et al. | Enhancing immune responses using suicidal DNA vaccines | |
| JP2019519252A5 (https=) | ||
| Hanke et al. | Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime | |
| Johansson et al. | Intradermal electroporation of naked replicon RNA elicits strong immune responses | |
| Ulmer et al. | DNA vaccines | |
| Rajčáni et al. | Current developments in viral DNA vaccines: shall they solve the unsolved? | |
| Dubensky Jr et al. | Delivery systems for gene-based vaccines | |
| Bivas-Benita et al. | Airway CD8+ T cells induced by pulmonary DNA immunization mediate protective anti-viral immunity | |
| JPWO2021216729A5 (https=) | ||
| Henke | DNA immunization–a new chance in vaccine research? | |
| Yue et al. | Evaluation of recombinant modified vaccinia Ankara virus-based rhesus cytomegalovirus vaccines in rhesus macaques | |
| WO2009141434A4 (en) | Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant | |
| US20060073123A1 (en) | Adenovirus vectors for immunotherapy | |
| Raz et al. | Deviation of the allergic IgE to an IgG response by gene immunotherapy | |
| Webster | Potential advantages of DNA immunization for influenza epidemic and pandemic planning | |
| Sherritt et al. | Effect of pre‐existing cytotoxic T lymphocytes on therapeutic vaccines | |
| Rollman et al. | HPV-16 L1 genes with inactivated negative RNA elements induce potent immune responses | |
| Sin et al. | Improving DNA vaccines targeting viral infection | |
| He et al. | Induction of T cell immunity by cutaneous genetic immunization with recombinant lentivector | |
| Watkins et al. | Analysis of reporter gene expression in ovine dermis and afferent lymph dendritic cells in vitro and in vivo | |
| CN113185586A (zh) | SARS-CoV-2编码蛋白来源的T细胞表位多肽及其应用 | |
| CN107812186A (zh) | C型CpG作为佐剂在HBV预防性以及治疗性疫苗中的应用及其制备方法 | |
| Ludewig | Dendritic cell vaccination and viral infection—animal models |